TrialSignal
Clinical trial intelligence report
Prospective Evaluation of the Predictive Value of PET in Patients With Diffuse Large B-cell-lymphoma Under R-CHOP-14. A Multicenter Study
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00544219
Status
COMPLETED
Phase
NA
Sponsor
Swiss Cancer Institute
Executive brief
Investment-Ready Snapshot
RATIONALE: Studying PET scans given to patients with cancer who are undergoing treatment may help doctors predict how patients will respond to treatment. PURPOSE: This clinical trial is studying PET scans in patients with diffuse large B-cell lymphoma who are receiving rituximab together with cyclophosphamide, doxorubicin, vincristine, and prednisone.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00544219
Indication
Lymphoma
Modality
monoclonal antibody
Target
rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, positron emission tomography
Intervention
rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, positron emission tomography
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.